MedTech Dive April 22, 2024
Nick Paul Taylor

Lumicell developed the technology to help physicians detect residual cancer in the breast cavity after surgery.

Dive Brief:

  • The Food and Drug Administration approved Lumicell’s breast cancer imaging tool, the company said Thursday.
  • Lumicell developed the Lumisystem imaging technology to enable surgeons to detect residual cancer in the breast cavity after performing a lumpectomy to remove the tumor.
  • An FDA advisory committee voted in March that the benefits of Lumisystem outweigh the risks, with one expert predicting the system will have the biggest impact on surgeons who have higher re-excision rates.

Dive Insight:

Lumisystem has two components called Lumisight and Lumicell DVS. Lumisight is a molecule that reacts to enzymes found at higher levels in and near tumor...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies, Medical Devices
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article